EN DE
Watch Bangkok Genomics Innovation Pcl for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Bangkok Genomics Innovation Pcl (BKGI) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Bangkok Genomics Innovation Pcl stock THB 1.66, price THB 2.30, that is 27.8% below the price, quality 48 out of 100. Rating: overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TH

BG Bangkok Genomics Innovation Pcl logo Thin data Nov 9, 2026

Bangkok Genomics Innovation Pcl

BKGI · BK
Expensive, weak quality

Our calculation puts a fair price 28% below what the stock costs today.

Solidly profitable · 17.7% net margin (TTM)
Ranks above peers (10/12)
Revenue last quarter +123% vs. a year ago.
Quality 48/100
Expensive Growth (revenue 5y +23.2 %/yr in THB)
2.2% dividend yield · Watch coverage
Moderate moat 63/100 · thin data
Fair value 1.66 THB · Overvalued
Negative free cash flow
Thin data
Watch Bangkok Genomics Innovation Pcl for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

5.11 THB 1.10 THB Fair Value 1.66 THB Mar 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

32‑month range 1.10 THB – 5.11 THB · fair‑value band 1.25 THB – 2.08 THB · the 2.30 THB price screens above the 1.66 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow Bangkok Genomics Innovation Pcl in your weekly email

Every Wednesday you see whether Bangkok Genomics Innovation Pcl is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Bangkok Genomics Innovation Public Company Limited provides medical analysis services in Thailand.

Show moreShow less

The company offers screening for fetal chromosomal abnormalities using non-invasive prenatal testing under the NIFTY brand, preimplantation chromosomal abnormality and thalassemia carrier gene screening, infectious disease group analysis, and monkeypox virus analysis.

It also provides other screening tests, such as cancer-related gene screening to predict the risk of inherited cancer, monitor treatment, select drugs that are appropriate for one's genetics, and provide treatment and disease prevention.

In addition, the company offers genetic analysis using whole exome sequencing, a technology that can detect gene abnormalities that cause diseases; individual genetic decoding, which involves detailed genetic sequencing to analyze genetic information and identify aspects such as ethnicity or ancestry, optimal exercise profiles, metabolic capabilities, and the risk of genetic diseases; newborn screening; and health check-ups for various needs.

Further, it supports research services in both medical and other fields, offers DNA and RNA sequencing, metabolomics and proteomics services, and medical products comprising genetic sequencers; NIPT, PGT-A, hereditary cancer screening, and precision oncology solutions; real-time PCR that includes beta thalassemia genotyping and human papillomavirus genotyping kits; and cell-free DNA storage tubes.

The company serves government sectors such as medical schools and health centers, as well as private sectors such as clinics, hospitals, private medical laboratories, research institutes, and universities.

Bangkok Genomics Innovation Public Company Limited was founded in 2017 and is headquartered in Bangkok, Thailand.

Stock analysis

Bangkok Genomics Innovation Pcl (BKGI) currently trades at 2.30 THB, while our model-based Fair Value estimate is 1.66 THB, 28% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 2.07 THB per share, and 2 of the 16 models we run sit above the 2.30 THB price.

Bear case: the Dividend Discount group reads lowest at 0.5350 THB, and 14 of the 16 models stay below the price. Data coverage for this calculation is low.

Scenario range: 1.25 THB (bear) to 2.08 THB (bull), the price of 2.30 THB sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Bangkok Genomics Innovation Pcl reported revenue of 380M THB in FY2025 versus 379M THB in FY2021, a compound +0.0%/yr. Reported net income was 45.3M THB in FY2025, compounding −19.1%/yr from FY2021.

Key figures

Market cap 1.4B THB (≈ $41.9M) Micro · P/E ratio 14.4 · P/S ratio 2.60 · EPS (TTM) 0.1600 THB · Dividend yield 2.2% · Net margin 17.7% · Return on equity 17.1% · Return on assets (EBIT) 20.8% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 63 out of 100 (low confidence).

What moves the price

The share trades about 10% below its 52-week high and 94% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −28%, BKGI screens richer than that median.

Fair Value models

Bear 1.25 THB Fair Value 1.66 THB Bull 2.08 THB
Price 2.30 THB · Downside -27.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.0943 THB per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income 0.7000 THB 0.7300 THB 0.7900 THB 76
EPV 0.8200 THB 0.8800 THB 0.9200 THB 70
ROIC Compounder 0.8200 THB 0.8800 THB 0.9300 THB 70
All 16 models by family
Earnings-Based
Graham-Dodd 0.5100 THB 3.50 THB 4.91 THB 63
Lynch FV 1.03 THB 1.47 THB 1.91 THB 61
PEG = 1.0 1.03 THB 1.47 THB 1.91 THB 57
EPV 0.8200 THB 0.8800 THB 0.9200 THB 70
Dividend Discount
Gordon GGM 0.3300 THB 0.5500 THB 0.7100 THB 68
DDM Multi-Stage 0.3300 THB 0.5200 THB 0.5900 THB 67
Multiples
P/E Multiple 1.25 THB 1.66 THB 2.08 THB 63
P/S Multiple 0.9600 THB 1.28 THB 1.61 THB 58
P/B Multiple 2.97 THB 3.96 THB 4.95 THB 55
EV/EBIT 1.21 THB 1.51 THB 1.81 THB 63
EV/EBITDA 1.43 THB 1.80 THB 2.17 THB 64
EV/Revenue 0.9500 THB 1.22 THB 1.50 THB 52
Asset-Based
NCAV (Graham) 0.4700 THB 0.7200 THB 0.9000 THB 52
Economic Profit
Residual Income 0.7000 THB 0.7300 THB 0.7900 THB 76
ROIC Compounder 0.8200 THB 0.8800 THB 0.9300 THB 70
Growth Earnings
Growth-Adj P/E 1.45 THB 2.07 THB 2.69 THB 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 48/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 43
How much profit the company makes from its sales and capital
Quality Growth 35
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 19
Does it invest with discipline instead of growing at any price?
Low Volatility 40
How calm the share price moves, does not count
Price momentum 85
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 87
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+12.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.2%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.1%
What shareholders gained per year (last 5 years), in THB ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in THB: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−2.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−4.9%
Dividend (yield on the price)2.2%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 11%
⚠ Revenue per share shrinking 4.4%/yr over ~5Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

BKGI screens overvalued: fair value 28% below the price. Compare with Thermo Fisher Scientific Inc →

Compare Bangkok Genomics Innovation Pcl with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks

Beats the industry median on 10/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 48 · Below median
Fair Value upside −27.8% · Above median
Profitability
Return on equity (12 months) 17.1% · Top 25%
Return on assets 6.5% · Top 25%
Net margin (12 months) 17.7% · Top 25%
Operating margin (12 months) 21.5% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 122.6% · Top 25%
Dividend yield (12 months) 2.2% · Above median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (12 months) 14.4× · Cheapest 25%
P/B 2.54× · Pricier than median
P/S (12 months) 2.60× · Cheaper than median
EV/EBITDA 9.6× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 39
PAST (return on equity)69 · sector 15
HEALTH (low debt)0 · sector 95
DIVIDEND (yield)43 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥147.00 ¥164.66 +12% vs BKGI
IQVIA Holdings IQV $271.83 $299.01 +10% vs BKGI
Illumina, Inc ILMN $213.13 $234.44 +10% vs BKGI
Thermo Fisher Scientific Inc TMO $694.76 $686.04 −1% vs BKGI
Danaher Corporation DHR $230.25 $209.18 −9% vs BKGI
IDEXX Laboratories, Inc IDXX $676.04 $496.48 −27% vs BKGI
Mettler-Toledo International Inc MTD $1,722 $655.06 −62% vs BKGI
Agilent Technologies, Inc A $174.76 $64.53 −63% vs BKGI
Lonza Group LONN CHF 663.40 CHF 153.50 −77% vs BKGI
Waters Corporation WAT $457.60 $91.26 −80% vs BKGI

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bangkok Genomics Innovation Pcl: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Bangkok Genomics Innovation Pcl Fair Value". https://www.fairvalue-calculator.com/stock/BKGI

Frequently asked questions

Is Bangkok Genomics Innovation Pcl (BKGI) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 1.66 THB versus a price of 2.30 THB, about 28% lower (overvalued).
What is the fair value of BKGI?
Our model-based fair value for Bangkok Genomics Innovation Pcl is 1.66 THB (as of Nov 9, 2026), built from audited fundamentals. The current price: 2.30 THB.
What is the quality score of BKGI?
Bangkok Genomics Innovation Pcl has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bangkok Genomics Innovation Pcl (BKGI)?
Our model-based price target is the fair value of 1.66 THB (as of Nov 9, 2026) from 16 valuation models. Cautious scenario 1.25 THB, optimistic scenario 2.08 THB. It is a calculation from audited fundamentals, not an analyst target.
What is the Bangkok Genomics Innovation Pcl stock forecast for 2026?
Our models put fair value at 1.66 THB, about 28% lower versus a price of 2.30 THB (overvalued). Cautious scenario 1.25 THB, optimistic scenario 2.08 THB. The calculation is refreshed regularly with new filings.
What is the revenue of Bangkok Genomics Innovation Pcl (BKGI)?
Bangkok Genomics Innovation Pcl reported trailing-twelve-month revenue of about 539M THB (latest available figure, as of Nov 9, 2026).
Does Bangkok Genomics Innovation Pcl pay a dividend?
Bangkok Genomics Innovation Pcl currently shows a dividend yield of 2.17% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Bangkok Genomics Innovation Pcl (BKGI) and when is the ex-dividend date?
Bangkok Genomics Innovation Pcl pays a dividend of 0.05 THB per share a year, a dividend yield of 2.2%. The last ex-dividend date was May 6, 2026. The payout ratio is 31.3% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Bangkok Genomics Innovation Pcl (BKGI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bangkok Genomics Innovation Pcl it is 1.66 THB per share (as of Nov 9, 2026), against a price of 2.30 THB. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Bangkok Genomics Innovation Pcl stock overvalued or undervalued in 2026?
As of Nov 9, 2026, BKGI trades above its calculated fair value: price 2.30 THB, fair value 1.66 THB, a gap of about −28% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BKGI?
No. The price is what the market pays today (2.30 THB); the fair value is what the company's own numbers justify (1.66 THB). For Bangkok Genomics Innovation Pcl the two are 0.6400 THB per share apart. That gap is exactly why we show both numbers side by side.
How much is Bangkok Genomics Innovation Pcl worth?
The market values Bangkok Genomics Innovation Pcl at about 1.4B THB (market capitalisation, as of Nov 9, 2026). Per share that is 2.30 THB; our models calculate a fair value of 1.66 THB per share.
What do the bullish and bearish scenarios say about BKGI?
Our models span a range for Bangkok Genomics Innovation Pcl: cautious scenario 1.25 THB, base 1.66 THB, optimistic 2.08 THB per share (as of Nov 9, 2026, price 2.30 THB). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BKGI?
Bangkok Genomics Innovation Pcl trades at a price-to-earnings ratio of 14.4 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1.66 THB is built from several models across several years. Other multiples: P/B 2.5, P/S 2.6, EV/EBITDA 9.6.
How solid is the balance sheet of Bangkok Genomics Innovation Pcl (BKGI)?
Balance-sheet figures for Bangkok Genomics Innovation Pcl (as of Nov 9, 2026): return on equity 17.1%. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is BKGI from its 52-week high?
Bangkok Genomics Innovation Pcl trades at 2.30 THB, about 10% below its 52-week high of 2.56 THB and 94% above the low of 1.19 THB (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 1.66 THB is for.
Which stocks are comparable to Bangkok Genomics Innovation Pcl?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bangkok Genomics Innovation Pcl stock attractive at the current price?
The data as of Nov 9, 2026: price 2.30 THB, calculated fair value 1.66 THB (−28%), Quality Score 48/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BKGI calculated?
We run Bangkok Genomics Innovation Pcl through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 1.66 THB builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Bangkok Genomics Innovation Pcl itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bangkok Genomics Innovation Pcl (BKGI)?
The closing price on Nov 6, 2026 was 2.30 THB. Our model-based fair value is 1.66 THB, about 28% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bangkok Genomics Innovation Pcl right now?
The price sits above even our optimistic bull case (2.08 THB). The favourable scenario is already priced in. Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Bangkok Genomics Innovation Pcl

How large is the market capitalisation of Bangkok Genomics Innovation Pcl (BKGI)?
The market capitalisation of Bangkok Genomics Innovation Pcl is 1.4B THB (≈ $41.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bangkok Genomics Innovation Pcl (BKGI)?
The price-to-sales ratio of Bangkok Genomics Innovation Pcl is 2.60 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bangkok Genomics Innovation Pcl (BKGI)?
Earnings per share at Bangkok Genomics Innovation Pcl are 0.1600 THB (price ÷ EPS = P/E 14.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Bangkok Genomics Innovation Pcl (BKGI)?
The dividend yield of Bangkok Genomics Innovation Pcl is 2.2% (payout 31.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Bangkok Genomics Innovation Pcl (BKGI)?
The net margin of Bangkok Genomics Innovation Pcl is 17.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bangkok Genomics Innovation Pcl (BKGI)?
The return on equity (ROE) of Bangkok Genomics Innovation Pcl is 17.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bangkok Genomics Innovation Pcl (BKGI)?
On an EBIT basis the return on assets of Bangkok Genomics Innovation Pcl is 20.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bangkok Genomics Innovation Pcl (BKGI)?
The operating margin of Bangkok Genomics Innovation Pcl is 21.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bangkok Genomics Innovation Pcl (BKGI)?
Revenue at Bangkok Genomics Innovation Pcl is growing +123% versus a year earlier (3y avg +7.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bangkok Genomics Innovation Pcl (BKGI)?
Earnings per share at Bangkok Genomics Innovation Pcl are growing +619% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Bangkok Genomics Innovation Pcl (BKGI) generate?
The free cash flow of Bangkok Genomics Innovation Pcl is −124M THB (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Bangkok Genomics Innovation Pcl (BKGI) hold?
Bangkok Genomics Innovation Pcl holds more cash than debt, 184M THB net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Bangkok Genomics Innovation Pcl in the live analysis

One click puts Bangkok Genomics Innovation Pcl on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.